A New Light in Neurology: Trio Awarded Nobel Prize in Medicine

Anupam Guha

October 6, 2026   

The Nobel Committee at the Karolinska Institute has announced that American scientist Karl Deisseroth and German scientists Peter Hegemann and Georg Nagel have jointly won the 2026 Nobel Prize in Medicine for their contributions to "Optogenetics". The trio are being recognized for research showing how "Light-sensitive Ion Channels" can be used to control nerve cells, particularly neurons in the brain. The prize was announced in Stockholm, Sweden.

Deisseroth is a scientist at Stanford University’s medical institute in the United States. Hegemann is affiliated with Humboldt University in Berlin, while Nagel is a professor at the University of Würzburg in Germany. According to the Nobel Committee, Karl Deisseroth, Peter Hegemann and Georg Nagel are being awarded the 2026 Nobel Prize in Medicine for their discoveries related to “Light-gated Ion Channels” and Optogenetics. Thomas Perlmann, secretary of the Nobel Committee for Medicine, announced the award on October 5. Each year, the Nobel Prize in Medicine recognizes important discoveries in the life sciences or medicine—work that has transformed scientific understanding or brought significant benefits to humanity. The announcement of the Medical  Science  reward on October 5, marked the start of this year’s Nobel Prize announcements. It was the first of six prizes to be announced over eight days, alongside those in Physics, Chemistry, Literature, Peace and Economic Sciences. The prize consists of a medal, a diploma and a cash award. The 2026 prize money has been set at 12 million Swedish kronor. The award ceremony will take place in December-2026.

Hegemann and Georg Nagel discovered a special protein called channelrhodopsin in single-celled algae. The protein makes cells sensitive to light. Deisseroth later developed a way to use it as a light-controlled switch in nerve cells. This technology allows researchers to use light to turn specific living brain cells, or neurons, on or off with millisecond precision. Deisseroth successfully introduced the light-sensitive protein discovered by Nagel and Hegemann into neurons in the living brains of mammals, such as mice. The new technology, combining genetic engineering and optics, is known as Optogenetics.

According to the Nobel Committee, the technology’s most significant practical applications are in treating disorders of the brain and eyes. Among the brain’s billions of neurons, it was once nearly impossible to identify which specific neural circuits were responsible for a particular disorder. Optogenetics now allows researchers to observe more precisely how the activity of these cells is controlled. This is helping them investigate the causes of complex conditions such as Parkinson’s disease, Alzheimer’s disease and epilepsy. The technology may also help people with serious eye diseases such as retinitis pigmentosa and Stargardt disease, in which the light-sensitive cells of the retina are damaged or at risk of damage. Researchers can make other surviving retinal cells artificially sensitive to light. Building on the work of the American-German trio, clinical trials of optogenetic gene therapy have already succeeded in partially restoring vision in people who are blind.

Karl Deisseroth (born November 18, 1971) is a prominent American neuroscientist, bioengineer and psychiatrist. He is a professor of bioengineering and of psychiatry and behavioral sciences at Stanford University in the United States. Peter Hegemann (born December 11, 1954) is a prominent German experimental biophysicist and a professor at Humboldt University of Berlin. Georg Nagel (born August 24, 1953) is a distinguished biophysicist and professor at the University of Würzburg in Germany. Dr. Deisseroth is internationally known for developing and advancing Optogenetics. This technology combines genetic engineering with light to switch specific neurons in a living animal’s brain—such as a mouse—on or off with millisecond precision. Until recently, it was difficult to determine precisely how neurons control human sensations, memories, behavior and disease. This breakthrough has ushered in a new era of neuroscience research. The researchers’ work also led to CLARITY, a hydrogel-based tissue-clearing method that makes brain tissue transparent while preserving its structural components. This allows scientists to study the brain’s complex circuits and networks in three dimensions.

While studying the single-celled green alga "Chlamydomonas reinhardtii", Peter Hegemann and Georg Nagel discovered a special type of protein called channelrhodopsin. They observed that the alga could swim toward light. Their research showed that when exposed to blue light, channelrhodopsin opens like an electrical gate—an ion channel—triggering an electrical impulse inside the cell. Later, Karl Deisseroth used genetic engineering to introduce this protein into specific neurons in the brains of living animals, such as mice. This made those brain cells sensitive to light. Optogenetics is a biological technique that combines optics (light) and genetics. First, a gene for a light-sensitive protein, such as channelrhodopsin, is delivered—often using a virus—to selected neurons in the brain. When laser or LED light is directed at these neurons through an optical fiber, the protein channels open. Researchers are using light to investigate and potentially correct faulty brain circuits associated with complex conditions such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, epilepsy, severe depression and addiction. The technique has also raised hopes in experimental research aimed at restoring vision by introducing light-sensitive proteins into damaged retinal cells. Their fundamental discovery is now regarded as one of the most powerful and transformative tools in modern neuroscience for investigating the brain’s complex workings. Optogenetics is a groundbreaking technology that uses light to activate or inhibit specific neurons in the brain of a living organism. In 2005, Karl Deisseroth, Peter Hegemann, Georg Nagel and their colleagues published a landmark study demonstrating the technique.

The discovery was based on light-sensitive proteins, including channelrhodopsin, found in green algae and other microorganisms. When illuminated, these proteins open pathways in the cell membrane, allowing electrically charged particles called ions to pass through. Using genetic engineering, Deisseroth and his colleagues introduced the gene for this light-sensitive protein into mouse neurons. They then used optical fibers to deliver light deep into the brain and stimulate the targeted neurons. By 2007, researchers had demonstrated this “light-controlled switch” in the brains of living animals. Before optogenetics, brain activity was commonly investigated using electrical stimulation or drugs, which were less precise. Optogenetics now enables researchers to study the brain circuits involved in complex neurological and psychiatric conditions, including Parkinson’s disease, Alzheimer’s disease, depression, blindness and addiction. This foundational work helped establish optogenetics as a field. By allowing researchers to control specific neurons with light, the technique has transformed the study of the brain’s structure, memory, emotions and neurological disorders.

The Nobel Prize in Physiology or Medicine has recognized a major breakthrough in modern science: Optogenetics. This technology uses light to control specific brain cells and neural circuits, helping researchers investigate how the brain works and how neurological and psychiatric disorders develop. By switching selected neurons on or off and observing the effects, scientists can study brain activity with unprecedented precision. Optogenetics has transformed basic neuroscience and is advancing research into conditions such as Parkinson’s disease, depression and blindness. The researchers’ pioneering work has opened new paths toward understanding one of the body’s greatest mysteries: How the Brain works!

   

(Tripurainfo)

more articles...